Navigation Links
PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
Date:9/9/2011

OXFORD, England, September 9, 2011 /PRNewswire/ --

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

Dr Fintan Walton, CEO, PharmaVentures commented, "We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders.  With 20 years' experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site."

The facility is part of the recent integration of Astex Therapeutics Limited and SuperGen Inc. and provides an opportunity to build out a fully integrated CMC capability in a prime but low cost West Coast US location.  The site's team has significant experience in preclinical as well as Phase I, II and III drug product development as evidenced by over 30 patents and the successful oversight of a number of global regulatory filings.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals.  The transactions team has an established track record in generating outstanding value for PharmaVentures' clients and has assisted in over 100 transactions in the past 20 years.  

For enquiries regarding this opportunity or how we can help your company to achieve its business goals, please contact:

Dr Jansen Jacobs
Senior Advisor
PharmaVentures Ltd
jansen.jacobs@pharmaventures.com
+44-7951-205420


'/>"/>
SOURCE Pharma Ventures Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
8. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
9. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Bioptix, Inc. ... announced that on January 14, 2017 the Board of ... the Company will terminate certain employees associated with the ... The Company commenced terminations on January 16, 2017 and ... The Company may pay severance benefits in certain circumstances ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... YORK , January 20, 2017 ... current market conditions have influenced the most recent performances ... Therapeutics Inc. (NASDAQ: RGLS ), Abeona Therapeutics ... (NASDAQ: TBPH ), and Sage Therapeutics Inc. ... research report by Grand View Research, global Biotech market size is ...
(Date:1/20/2017)... 20, 2017 http://www.Financialbuzz.com ... of leading causes of death worldwide. There were 8.2 ... of cancer related deaths increased gradually over time, the ... rate of various cancers continues to drive demand of ... by Global Market Insights, Inc. cancer biological therapy market size ...
Breaking Biology Technology:
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):